Please login to the form below

I have forgotten my password

Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July

Large-scale study will include 30,000 individuals

FDA delays review of Novartis’ MS drug ofatumumab

Regulator now expected to deliver verdict on application in September

Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma

Challenges Johnson & Johnson’s Darzalex

ASCO: Momentum gathers behind next wave of CAR-T therapies

Update from Gilead and new data from J&J, BMS and others

Lilly starts world first trial of an antibody drug for COVID-19

Drug is the first to be specifically designed to treat the virus

Pfizer’s Ibrance misses the mark in early breast cancer

Drug was unable to demonstrate statistical significance in primary endpoint

ASCO: Merck’s Keytruda tops chemo in MSI-H colorectal cancer

PD-1 inhibitor more than doubled progression-free survival compared to chemotherapy

ASCO: Bavencio boosts survival post-chemo in bladder cancer

Merck KGaA and Pfizer report drug reduces risk of death by 31%

IFPMA industry association conference: ‘no-one left behind’ on coronavirus vaccine

CEOs of vaccine giants AZ, GSK, J&J and Pfizer pledge to pull out all the stops

Q&A: Kay Wesley

PME chats to the Chief Executive of Kanga Health Ltd and Town Councillor at Women’s Equality Party Congleton

Q&A: Elizabeth Egan

Elizabeth Egan is President of Havas Lynx Group
Current and future trends for developing digital medical communications

Evolving digital trends and user needs

Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir

The 450-patient phase 3 trial combines an antiviral with an immune modulator
GSK plans to produces one billion doses of vaccine adjuvant for COVID-19

Company will support numerous vaccine candidates
UK government launches NHS test and trace service

New service initiated as part of national recovery strategy and aims to test and trace every suspected case of coronavirus in the country
EMA clears BMS’ oral multiple sclerosis drug Zeposia

EvaluatePharma estimates drug could earn $1.6bn in 2024
Gilead shells out $375m for immuno-oncology deal with Arcus

Wide-ranging deal gives company access to bulk of biotech’s immuno-oncology pipeline
UK clears NHS use of Gilead’s remdesivir for COVID-19 patients

MHRA approved the drug under the Early Access to Medicines Scheme
Merck buys Themis as part of drive for COVID-19 drugs and vaccines

Deal also adds a pipeline of vaccines for other infectious diseases as well as cancer

Latest appointments

Dan Russell joins Seven Stones as managing director

Joins the team to help drive global expansion
McCann Health France strengthens team with two new hires

Melissa Brunet and Christelle David-Basei join the agency
Ashfield appoints new global head of quality and compliance

Internal candidate Carey Galvin to take on the role
NICE looks internally for new chief executive

Deputy chief exec Gillian Leng is set to take the helm
AstraZeneca taps internal candidate to become UK president

Tom Keith-Roach has worked at the company for 17 years

More appointments

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Working together against COVID-19: Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19: Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?: Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Quick links

Infographics

Multimedia

<>